Malcolm Spicer, Managing Editor – US
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Malcolm Spicer
Across all 9 IMF facilities in FY 2019, FDA screened around 25,200 parcels containing more than 41,000 products, detained more than 38,000 including 1,801 identified as supplements and expects to destroy more than 17,000.
Business continues selling unapproved and misbranded drugs due to claims for products intended to be used as Chinese herbal medicines including treatment of autism, Alzheimer’s disease, herpes and cancer, says FDA says warning.
Trump administration negotiations with China representatives led to US suspending tariff increase to 25% on product categories announced set to begin 15 October. But 15% tariff added in September on about $112bn worth of Chinese goods remains and US still plans in December to impose separate 10% tariff hike on $160bn in other products.
As it prepares to be acquired, firm unveils first redesigned store in Edgewater, NJ, and plans five additional locations to open with a similar format through January. The "store is a great example of our ongoing transformation into an agile, customer-centric company," says CEO Sharon Leite.
Ibitta's response didn't provide sufficient documentation and other evidence indicating it will correct GMP problems found during FDA's May inspection. Warning also states some of firm's products are mis-branded, including stating information in two languages without repeating all required information in both languages.
Businesses such as Post's "Active Nutrition" division not only help drive overall sales, they also represent opportunities to create new value. "You can see a rationale for a larger company trying to unlock value," says L.E.K analyst Alex Evans.